Drug Pricing and Cost Publications

Coverage, Formulary Restrictions, and Out-of-Pocket Costs for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Medicare Part D Program
Jing Luo, MD, MPH; Robert Feldman, MS; Scott D. Rothenberger, PhD; Inmaculada Hernandez, PharmD, PhD; Walid F. Gellad, MD, MPH
JAMA Network Open, October 15, 2020

Effect of Carving in Pharmacy Benefits on Utilization and Costs
Natasha Parekh , MD, MS, Sarah Papa , MS, Alek Drnach , MS, Laura Spiegel , BS, Yan Huang , MS, Chronis Manolis , RPh, Chester B. Good , MD, MPH
Journal of Managed Care and Specialty Pharmacy, October 2020

Estimating Discounts for Top Spending Drugs in Medicare Part D
Inmaculada Hernandez PharmD, PhD, Alvaro San-Juan-Rodriguez PharmD, Chester B. Good MD, MPH & Walid F. Gellad MD, MPH 
Journal of General Internal Medicine, September 9, 2020

Drug Shortages and Group Purchasing Organizations-Reply
Julie M Donohue, Inmaculada Hernandez, Tina Batra Hershey
JAMA, August 25, 2020

Trends in List and Net Prices of Self-administered Systemic Psoriasis Therapies Manufactured by US-Based Pharmaceutical Companies
Laura K. Ferris, MD, PhD; Walid F. Gellad, MD, MPH; Inmaculada Hernandez, PharmD, PhD
JAMA Dermatology, August 12, 2020

Drug Prices, Rebates, and Discounts—Reply
Inmaculada Hernandez, PharmD, PhD; Walid F. Gellad, MD, MPH
JAMA, July 28, 2020

Cost and Access Implications of Defining CAR-T Therapy as a Drug
Rohan Chalasani, BA; Tina B. Hershey, JD, MPH; Walid F. Gellad, MD, MPH
JAMA Health Forum, July 22, 2020

The US Is Paying Way Too Much for Remdesivir
Rohan Chalasani and Walid Gellad
Wired, July 17, 2020

Initial Experience Prescribing Commercial Tafamidis, the Most Expensive Cardiac Medication in History
Ahmad Masri, MD, MS; Hongya Chen, PharmD; Catherine Wong, MD; Katherine L. Fischer, MSN, RN; Chafic Karam, MD; Walid F. Gellad, MD, MPH; Stephen B. Heitner, MD
JAMA Cardiology, June 17, 2020

Treatments don’t work if we can’t afford them: the global need for open and equitable access to remdesivir
Jing Luo, Gregg Gonsalves, Amy Kapczynski
The BMJ Opinion, June 3, 2020

National trends in prescription drug expenditures and projections for 2020
Eric M Tichy, PharmD, MBA, BCPS, FCCP, FAST, Glen T Schumock, PharmD, MBA, PhD, FCCP, James M Hoffman, PharmD, MS, Katie J Suda, PharmD, MS, Matthew H Rim, PharmD, MS, Mina Tadrous, PharmD, MS, PhD, JoAnn Stubbings, BSPharm, MHCA, Sandra Cuellar, PharmD, BCOP, John S Clark, PharmD, MS, BCPS, FASHP, Michelle D Wiest, PharmD, BCPS, FASHP, Linda M Matusiak, MPA, Robert J Hunkler, MBA, Lee C Vermeulen, BSPharm, MS, FCCP, FFIP
American Journal of Health-System Pharmacy, May 15, 2020

Insulin access and affordability in the USA: anticipating the first interchangeable insulin product
Jing Luo, Aaron S Kesselheim, Ameet Sarpatwari
The Lancet Diabetes and Endocrinology, March 20, 2020

Decreasing Health Care Spending Through Market Competition—A Case for the Rapid Adoption of Adalimumab Biosimilars
Jennifer D. Claytor, MD, MS; Walid Gellad, MD, MPH
JAMA Internal Medicine, March 30, 2020

The Skyrocketing Cost of Rectal Indomethacin
B. Joseph Elmunzer, MD, MSc; Inmaculada Hernandez, PharmD, PhD; Walid F. Gellad, MD, MPH
JAMA Internal Medicine, March 9, 2020

Drug Shortages in the United States: Are Some Prices Too Low?
Inmaculada Hernandez, PharmD, PhD; Tina Batra Hershey, JD, MPH; Julie M. Donohue, PhD
JAMA, March 3, 2020

Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018
Inmaculada Hernandez, PharmD, PhD; Alvaro San-Juan-Rodriguez, PharmD; Chester B. Good, MD, MPH; Walid F. Gellad, MD, MPH
JAMA, March 3, 2020

Differences Between Managed Care and Fee-for-Service Medicaid in the Use of Generics for High-Rebate Drugs: The Cases of Insulin Glargine and Glatiramer
Inmaculada Hernandez, PharmD, PhD, and Walid F. Gellad, MD, MPH
Journal of Managed Care & Specialty Pharmacy, February 2020

Origins of the Crisis in Insulin Affordability and Practical Advice for Clinicians on Using Human Insulin
Jing Luo, Walid F. Gellad
Current Diabetes Reports, January 29, 2020

Trends in List Prices, Net Prices, and Discounts for Originator Biologics Facing Biosimilar Competition
Alvaro San-Juan-Rodriguez, PharmD; Walid F. Gellad, MD, MPH; Chester B. Good, MD, MPH; Inmaculada Hernandez, PharmD, PhD
JAMA Network Open, December 13, 2019

Adalimumab and the Challenges for Biosimilars
Walid F. Gellad, MD, MPH; Chester B. Good, MD, MPH
JAMA, October 23, 2019

Review of purchases of unapproved medications by the Veterans Health Administration
Ron L Carico, Jr., Pharm.D., M.P.H, Thomas R Emmendorfer, Pharm.D, Sherrie L Aspinall, Pharm.D., M.Sc, Margaret T Mizah, Pharm.D, Chester B Good, M.D., M.P.H
American Journal of Health-System Pharmacy, October 19, 2019

Association between physician adoption of a new oral anti-diabetic medication and Medicare and Medicaid drug spending
Ilinca D. Metes, Lingshu Xue, Chung-Chou H. Chang, Haiden A. Huskamp, Walid F. Gellad, Wei-Hsuan Lo-Ciganic, Niteesh K. Choudhry, Seth Richards-Shubik, Hasan Guclu & Julie M. Donohue
BMC Health Services Research, October 16, 2019

Variation in Prescription Drug Prices by Retail Pharmacy Type: A National Cross-sectional Study
Jing Luo, MD, MPH; Martin Kulldorff, PhD; Ameet Sarpatwari, JD, PhD; Ajinkya Pawar, PhD; Aaron S. Kesselheim, MD, JD, MPH
Annals of Internal Medicine, October 1, 2019

Prescription 2020: Democratic Candidates And Drug Pricing
Rohan Chalasani, Julie M. Donohue, Walid F. Gellad
Health Affairs Blog, August 29, 2019

Trends in Prices, Market Share, and Spending on Self-administered Disease-Modifying Therapies for Multiple Sclerosis in Medicare Part D
Alvaro San-Juan-Rodriguez, PharmD; Chester B. Good, MD, MPH; Rock A. Heyman, MD; Natasha Parekh, MD, MS; William H. Shrank, MD, MSHS; Inmaculada Hernandez, PharmD, PhD
JAMA Neurology, August 26, 2019

Senate Hearings On Drug Prices: Many Questions, Few (Useful) Answers
Inmaculada Hernandez, Walid F. Gellad
Health Affairs Blog, July 24, 2019

Number of Manufacturers and Generic Drug Pricing From 2005 to 2017
Inmaculada Hernandez, PharmD, PhD; Chester B. Good, MD, MPH; Walid F. Gellad, MD, MPH; Natasha Parekh, MD, MS; Meiqi He, MS; and William H. Shrank, MD, MSHS
The American Journal of Managed Care, July 15, 2019

Savings from the EpiPen Authorized Generic: a Retrospective Analysis of Medicaid Data
Inmaculada Hernandez, William H. Shrank, Chester B. Good, Walid F. Gellad
Journal of General Internal Medicine, April 3, 2019

A New Safe Harbor — Turning Drug Rebates into Discounts in Medicare Part D
Walid F. Gellad, M.D., M.P.H., Molly Ennis, M.P.H., and Courtney C. Kuza, Ph.D., M.P.H.
The New England Journal of Medicine, April 3, 2019

Trends in Medicaid Prices, Market Share, and Spending on Long-Acting Insulins, 2006-2018
Inmaculada Hernandez, PharmD, PhD; Chester B. Good, MD, MPH; William H. Shrank, MD, MSHS; Walid F. Gellad, MD, MPH
JAMA, March 25, 2019

On The Use Of List Prices In Drug Pricing Research
Inmaculada Hernandez, Walid Gellad
Health Affairs Blog, March 14, 2019

Assessment of Price Changes of Existing Tumor Necrosis Factor Inhibitors After the Market Entry of Competitors
Alvaro San-Juan-Rodriguez, PharmD; Max V. Prokopovich, BS; William H. Shrank, MD, MSHS; Chester B. Good, MD, MPH; Inmaculada Hernandez, PharmD, PhD
JAMA Internal Medicine, February 18, 2019

Assessment of Spending in Medicare Part D If Medication Prices From the Department of Veterans Affairs Were Used
Brett Venker, PharmD; Kevin B. Stephenson, MD; Walid F. Gellad, MD, MPH
JAMA Internal Medicine, January 14, 2019

The Contribution Of New Product Entry Versus Existing Product Inflation In The Rising Costs Of Drugs
Inmaculada Hernandez, Chester B. Good, David M. Cutler, Walid F. Gellad, Natasha Parekh, and William H. Shrank
Health Affairs, January 7, 2019